Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics Stock Is Plunging Today

By Prosper Junior Bakiny - Feb 25, 2021 at 12:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not impressed with the drugmaker's latest quarterly update.

What happened?

Shares of Akebia Therapeutics (AKBA 2.53%) are falling sharply on Thursday after the company reported mixed fourth-quarter 2020 financial results. At 12:27 p.m. EST, the biopharmaceutical company's stock was down by 17.4%.

So what

Akebia Therapeutics' total revenue of $56.7 million for its fourth quarter, ending Dec. 31, beat the consensus analyst estimate, which was $51.16 million. The company's top line dropped by about 18.4% year over year due to a decline in its collaboration revenue. On the bottom line, Akebia Therapeutics reported a net loss of $87 million -- $0.60 per share -- compared to the net loss and net loss per share of $94.5 million and $0.79 respectively that it recorded during the fourth quarter of the previous fiscal year. 

Man holding his head in panic staring at a downward pointing graph on a board.

Image source: Getty Images.

On average, analysts expected the company's net loss per share to be $0.40. The bottom-line miss is probably contributing to Akebia Therapeutics' losses on the market today. For the full fiscal year 2020, the company's total revenue declined by roughly 11.8% to $295.3 million, although it came in ahead of the $288.47 million analysts were looking for. Akebia Therapeutics' net loss per share of $2.77 for the year came in well short of the $2.58 average estimate.

Now what

Akebia Therapeutics is gearing up to submit a new drug application to the U.S. Food and Drug Administration for Vadadustat as a treatment for anemia due to chronic kidney disease. The company estimates that Vadadustat could have a $2 billion opportunity in this market in the U.S. If approved, this medicine could become a major cash cow for the healthcare company

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics, Inc. Stock Quote
Akebia Therapeutics, Inc.
AKBA
$0.41 (2.53%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.